What is Orca Bio?
Orca Bio is a late-stage biotechnology firm dedicated to pioneering high-precision cell therapies for challenging conditions such as blood cancer and autoimmune diseases. Its proprietary manufacturing platform employs single-cell precision to engineer personalized cell therapy products. These advanced therapies are designed to effectively replace a patient's diseased blood and immune system with a healthy, functional one. Orca Bio's core mission is to redefine patient outcomes by transforming the landscape of curative allogeneic cell therapy through scientific innovation and strategic investment.
How much funding has Orca Bio raised?
Orca Bio has raised a total of $442M across 2 funding rounds:
Series D
$192M
Series F
$250M
Series D (2020): $192M with participation from ND Capital, Lightspeed Venture Partners, DCVC Management Co LLC, 8VC, and Mubadala
Series F (2026): $250M led by Lightspeed Venture Partners
Key Investors in Orca Bio
Lightspeed Venture Partners
Lightspeed Venture Partners is a global multistage venture capital firm that invests in early and growth-stage technology companies across various sectors, including enterprise software, consumer, fintech, and infrastructure.
8VC
8VC is a venture capital firm that focuses on investing in companies with a strong technological foundation and disruptive potential, often in sectors like biotech and enterprise software.
Mubadala
Mubadala is a global investment company based in Abu Dhabi, United Arab Emirates, with a mandate to create sustainable financial returns and foster economic diversification.
What's next for Orca Bio?
With a significant infusion of capital, Orca Bio is poised to accelerate its development and commercialization efforts. The company's focus on high-precision cell therapies suggests a strategic expansion of its manufacturing capabilities and clinical trial programs. This substantial backing, particularly the recent major strategic investment, indicates a strong belief in Orca Bio's technology and its potential to disrupt the treatment paradigm for blood cancers and autoimmune disorders. Future endeavors will likely involve scaling operations, advancing pipeline candidates through regulatory pathways, and potentially forging key partnerships to broaden market access and impact.
See full Orca Bio company page
